"10.1371_journal.pmed.0040157","plos medicine","2007-05-22T00:00:00Z","Luis Alberto García Rodríguez; Karine Egan; Garret A FitzGerald","Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain; The Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America","LAGR provided analysis of the database, interpretation of findings, and preparation of manuscript. KE provided concept of study. GAF provided concept of study, interpretation of findings, and preparation of manuscript.","The original dataset, which was the basis of a previous paper (Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez-Perez A (2004) Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 109: 3000–3006), was performed thanks to a research grant from Pharmacia (now Pfizer). KE has nothing to declare. LAGR receives unrestricted research grants from Pfizer and Novartis, both of which manufacture drugs that target COXs. GAF receives financial support for investigator-initiated research from Bayer, Merck, and Boehringer Ingelheim, all of which manufacture drugs that target COXs. GAF has also served as a consultant for Astra Zeneca, Bayer, Biolipox, Boehringer Ingelheim, deCode, Merck, GlaxoSmithKline, Genome Institute of the Novartis Foundation, Lilly, Novartis, NicOx and Via Pharmaceuticals.","2007","05","Luis Alberto García Rodríguez","LAGR",3,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
